[Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis]

Manuela Funke-Chambour; Thomas Geiser

doi:10.1024/0040-5930/a000751

[Anti-fibrotics as novel therapy for idiopathic pulmonary fibrosis]

Ther Umsch. 2016;73(1):25-9. doi: 10.1024/0040-5930/a000751.

[Article in German]

Authors

Manuela Funke-Chambour¹, Thomas Geiser¹

Affiliation

¹ 1 Universitätsklinik für Pneumologie, Inselspital, Bern.

PMID: 26884217
DOI: 10.1024/0040-5930/a000751

Abstract

Recent studies have shown efficacy to slow the decrease of forced vital capacity in patients with idiopathic pulmonary fibrosis. This summary refers to recent anti-fibrotic medications and describes current studies, indication for treatment and side effects, as well as discusses open questions of treatment.

Publication types

English Abstract
Review

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
Evidence-Based Medicine
Fibrinolytic Agents / administration & dosage*
Fibrinolytic Agents / adverse effects
Humans
Idiopathic Pulmonary Fibrosis / diagnosis*
Idiopathic Pulmonary Fibrosis / drug therapy*
Indoles / administration & dosage*
Indoles / adverse effects
Kidney Diseases / chemically induced
Kidney Diseases / prevention & control*
Pyridones / administration & dosage*
Pyridones / adverse effects
Respiratory System Agents / administration & dosage
Respiratory System Agents / adverse effects
Treatment Outcome

Substances

Anti-Inflammatory Agents, Non-Steroidal
Fibrinolytic Agents
Indoles
Pyridones
Respiratory System Agents
pirfenidone
nintedanib